Beximco Expands In US With Eight ANDAs From Sandoz
Beximco has bolstered its position in the US by bumping up its portfolio to 14 approved generics through a deal with Sandoz for a portfolio of eight ANDAs.
You may also be interested in...
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.
Bangladesh’s biggest pharmaceutical company, Beximco Pharmaceuticals, has posted a 16.7% jump in after-tax profit in its financial first half, powered by double-digit domestic and export revenue growth.
Shipping a fourth product to the US, as well as two launches in Canada, ensured exports accounted for more than a tenth of Bangladeshi producer Beximco’s half-year turnover.